Chinese households under lockdown have lacked food, company, and access to medical care. But they’ve had an almost endless supply of a traditional Chinese medicine treatment called Lianhua Qingwen, made by Yiling Pharmaceuticals. Chinese students abroad even have this drug delivered to their doorsteps in healthcare packages, and demand for it among diaspora communities has seen panic-buying and hugely inflated prices. In this episode, we explore why the Chinese state has invested huge sums in promoting such traditional remedies that have not been subject to rigorous clinical testing. To unpack the history and the politics, Louisa and Graeme are joined by Michael Stanley-Baker, historian of Chinese medicine and religion at Nanyang Technological University and Altman Yuzhu Peng, researcher of intercultural communications at the University of Warwick.